Roots Analysis
has announced the addition of “Endocannabinoid
System Targeted Therapeutics Market, 2020-2030” report
to its list of offerings.
Over time, extensive R&D on the
potential health benefits of cannabis, have enabled medical researchers to
identify a number of pharmacologically active ingredients that offer clinical
benefit, minus the addictive properties of the crude substance. Currently,
several stakeholders in the pharmaceutical industry are actively engaged in the
efforts to develop leads based on natural and synthetic derivatives of cannabinoids.
To order this 250+ page report, which features 140+ figures and 170+
tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key
arket Insights
Over 175 drugs targeting
the endocannabinoid system are currently under
development
Most cannabinoid-based drug candidates
are being developed to target the CB1 and CB2 receptors. Nearly 45% of such drugs
are presently being investigated in clinical trials, while 50% are in the
preclinical / discovery phase. Majority of these therapies (60%) are designed
for oral administration.
More than 60 companies claim to
develop endocannabinoid system targeted therapeutics
Post 2010, there has been a
significant rise in the number of companies working in this domain; such
companies represent 63% of the total number of players. Majority of the firms
engaged in this domain (74%) are based in North America, followed by those
headquartered in Asia-Pacific (16%), Europe (8%) and Latin America (2%).
Partnership activity has
grown at an annualized rate of 35%, between 2017 and 2019
The maximum number of partnerships
were observed in 2019 within this segment of the pharmaceutical industry.
ajority of these agreements were reported to have been inked for research
purposes (20%). In addition, more than 35 merger / acquisition deal were signed
between 2016 and 2020; service / facility expansion emerged as the most
prominent key value drivers for such agreements.
Close to 600 grants were awarded for supporting
research on endocannabinoid system targeted therapeutics, since 2016
Almost 45% of the total amount awarded
in the form of grants, was under the R01 (in support of health-related research
and development based on the mission of the NIH) mechanism. Further, grants (394)
worth USD 147 million were awarded to research projects related to
endocannabinoid system.
At present, therapies intended for the
treatment of neurological disorders represent the majority share of the overall
endocannabinoid system targeted therapeutics market
Most of the therapies targeting neurological
disorders are intended for the treatment of epilepsy. In addition to neurological
disorders, therapies intended for autoimmune disorders, cancer and genetic
disorders are likely to capture significant market opportunity in the foreseen future.
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
Key
Questions Answered
§ Who are the leading industry players in this
market?
§ What are the key clinical conditions addressed
by endocannabinoid system targeted therapeutics?
§ What are the biological receptors targeted by
cannabinoid-based therapies?
§ What are the factors that are likely to
influence the evolution of this market?
§ What are the initiatives undertaken by start-ups
and big pharma players engaged in this domain?
§ What kind of partnership models are commonly
adopted by stakeholders in this industry?
§ How is the current and future market
opportunity likely to be distributed across key market segments?
The over USD 5 billion (by 2030) financial
opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across
the following segments:
§ Target
Disease Indication
- Cancer
- Genetic Disorders
- Neurological Indications
- Others
§ Route of Administration
- Oral
- Inhalation
§ Key Geographies
- North America
- Europe
- Asia-Pacific and the Rest of the World
The report features inputs from
eminent industry stakeholders, according to whom, endocannabinoid system
targeted therapeutics are considered as a promising alternative for the
treatment of a diverse array of symptoms associated with a myriad of human diseases.
The report includes detailed transcripts of the discussions held with industry experts.
§ Oludare Odumosu (Chief
Executive Officer, Zelira Therapeutics)
§ Andrea Small-Howard (Chief
Scientific Officer, GB Sciences)
§ Steeve Néron (Chief
Operating Officer, Tetra Bio-Pharma)
§ Stephen Dahmer (Chief
edical Officer, Vireo
Health)
§ Anthony Kievid (Director of
Business Development, Echo Pharmaceuticals)
§ JANAKAN KRISHNARAJAH (Chief
Operating Officer and Chief Medical Officer, iX Biopharma)
The research includes detailed
profiles of key players (listed below); each profile features an overview of
the company, its financial information (if available), drug portfolio, recent
developments and an informed future outlook.
§ GW Pharmaceuticals
§ Corbus Pharmaceuticals
§ Tilray
§ Tetra Bio-Pharma
§ Botanix Pharmaceuticals
§ Kalytera Therapeutics
§ Therapix Biosciences
§ Echo Pharmaceuticals
§ Avicanna
§ GB Sciences
For additional details, please
visit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html or email sales@rootsanalysis.com
You may also be interested in the
following titles:
1. Neoantigen Targeted Therapies Market, 2019-2030
2. Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on
Non-Invasive Drug Delivery Technology Platforms and Therapeutics
3. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030
About
Roots Analysis
Roots
Analysis is one of the fastest growing market research companies, sharing fresh
and independent perspectives in the bio-pharmaceutical industry. The in-depth
research, analysis and insights are driven by an experienced leadership team
which has gained many years of significant experience in this sector. If you’d
like help with your growing business needs, get in touch at
info@rootsanalysis.com
Contact
Information
Roots Analysis Private Limited
Ben
Johnson
+1
(415) 800 3415